Stellate ganglion blockade cuts menopause symptoms

Stellate ganglion blockade cuts menopause symptoms

(HealthDay)—For postmenopausal women, stellate ganglion blockade (SGB) significantly reduces objective measures of vasomotor symptoms (VMS), according to a study published online Feb. 3 in Menopause.

David R. Walega, M.D., from the Feinberg School of Medicine at Northwestern University in Chicago, and colleagues randomized 40 (aged 30 to 70 years) with moderate to severe VMS to image-guided SGB (performed with 5 mL of 0.5 percent bupivacaine) or sham injection of saline to the subcutaneous neck tissues. VMS were noted at baseline and for six months. Ambulatory sternal skin conductance monitoring was used to measure objective VMS over a 24-hour period at baseline and on three-month follow-up.

The researchers found that, while there were no significant between-group differences in overall VMS frequency, in the active group, there was a greater reduction in the frequency of moderate to very severe VMS compared with the sham treatment group (event rate ratio, 0.50; P < 0.001). In the SGB group, the frequency of objective VMS was further reduced compared with the sham group (event rate ratio, 0.71; P < 0.05). No study-related serious adverse events were reported.

"SGB may provide effective treatment of VMS in who seek nonhormonal treatments because of safety concerns and personal preference," the authors write. "The finding that SGB significantly reduces objectively measured VMS provides further evidence of efficacy."

Several authors disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Nerve block eases troublesome hot flashes

date Feb 05, 2014

Injecting a little anesthetic near a nerve bundle in the neck cut troublesome hot flashes significantly, shows a new randomized, controlled trial published online today in Menopause, the journal of The North American Menopa ...

Romosozumab increases bone mineral density post-menopause

date Jan 06, 2014

(HealthDay)—Romosozumab seems safe and effective for increasing bone mineral density in postmenopausal women with low bone mineral density, according to a study published online Jan. 1 in the New England Jo ...

Recommended for you

Rotational instrument delivery OK for fetal malposition

date Mar 24, 2015

(HealthDay)—Neonatal outcomes are no worse with rotational instrumental delivery than with cesarean delivery for persistent fetal malposition, according to a study published in the March issue of the American Jo ...

Shoulder dystocia maneuvers not tied to neonatal harm

date Mar 23, 2015

(HealthDay)—A variety of shoulder dystocia maneuvers are not associated with neonatal morbidity after adjusting for duration, according to a study published in the March issue of the American Journal of ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.